Back to results
US 2014/0178306 A1Published application
Steatohepatitis-liver cancer model animal
AssigneeStelic Institute of Regenerative Medicine, Stelic Institute & Co.
InventorsHIROYUKI YONEYAMA, MASATO FUJII
Life of this patent
Estimating the term…
Abstract
Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.
Claims8
-11. (canceled)
A non-human animal model, which is produced by:
- (a) administering to a non-human animal of one to five days old an N-acetyl-β-D-glucosaminidase inhibitor in an amount sufficient to induce organ inflammation;
- and
- (b) rearing the animal with a high-fat diet over a period of time sufficient to induce:
- (i) massive type cord-like liver cell carcinoma;
- (ii) infiltration of inflammatory cells;
- or
- (iii) liver cancer caused by cirrhosis developed such that it displaces normal liver cells of the animal.
4 more elements
(canceled)
Dependencies are inferred from the claim text.